Bicycle Therapeutics plc (BCYC): Price and Financial Metrics
GET POWR RATINGS... FREE!
BCYC POWR Grades
- Stability is the dimension where BCYC ranks best; there it ranks ahead of 26.51% of US stocks.
- The strongest trend for BCYC is in Quality, which has been heading down over the past 179 days.
- BCYC's current lowest rank is in the Growth metric (where it is better than 1.61% of US stocks).
BCYC Stock Summary
- BICYCLE THERAPEUTICS PLC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 10.89% of US listed stocks.
- BCYC's price/sales ratio is 52.08; that's higher than the P/S ratio of 96.51% of US stocks.
- The volatility of BICYCLE THERAPEUTICS PLC's share price is greater than that of 86.25% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to BCYC, based on their financial statements, market capitalization, and price volatility, are RETA, AIP, TUYA, PACB, and ATOM.
- Visit BCYC's SEC page to see the company's official filings. To visit the company's web site, go to www.bicycletherapeutics.com.
BCYC Valuation Summary
- In comparison to the median Healthcare stock, BCYC's price/sales ratio is 2665% higher, now standing at 55.3.
- Over the past 43 months, BCYC's price/earnings ratio has gone up 1.4.
Below are key valuation metrics over time for BCYC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BCYC | 2022-11-25 | 55.3 | 2.9 | -8.3 | -5.2 |
| BCYC | 2022-11-23 | 53.6 | 2.8 | -8.0 | -4.9 |
| BCYC | 2022-11-22 | 55.4 | 2.9 | -8.3 | -5.2 |
| BCYC | 2022-11-21 | 52.7 | 2.7 | -7.9 | -4.8 |
| BCYC | 2022-11-18 | 54.5 | 2.8 | -8.1 | -5.0 |
| BCYC | 2022-11-17 | 54.0 | 2.8 | -8.1 | -5.0 |
BCYC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BCYC has a Quality Grade of D, ranking ahead of 14.02% of graded US stocks.
- BCYC's asset turnover comes in at 0.053 -- ranking 317th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BCYC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.053 | 1 | -2.208 |
| 2021-06-30 | 0.058 | 1 | -2.188 |
| 2021-03-31 | 0.066 | 1 | -2.778 |
| 2020-12-31 | 0.072 | 1 | -4.530 |
| 2020-09-30 | 0.090 | 1 | -3.997 |
| 2020-06-30 | 0.073 | 1 | -4.570 |
BCYC Stock Price Chart Interactive Chart >
BCYC Price/Volume Stats
| Current price | $31.73 | 52-week high | $61.50 |
| Prev. close | $28.89 | 52-week low | $12.08 |
| Day low | $28.63 | Volume | 607,900 |
| Day high | $31.93 | Avg. volume | 345,866 |
| 50-day MA | $24.93 | Dividend yield | N/A |
| 200-day MA | $26.27 | Market Cap | 942.03M |
Bicycle Therapeutics plc (BCYC) Company Bio
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Latest BCYC News From Around the Web
Below are the latest news stories about BICYCLE THERAPEUTICS PLC that investors may wish to consider to help them evaluate BCYC as an investment opportunity.
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) Programs at the SITC 37th Annual MeetingBicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that preclinical data for BT7480, a novel Bicycle tumor-targeted immune cell agonist (Bicycle TICA), and BT7455, an EphA2/CD137 Bicycle TICA, will be presented in five poster presentations at the |
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual MeetingCAMBRIDGE, England, & BOSTON, November 10, 2022--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that preclinical data for BT7480, a novel Bicycle tumor-targeted immune cell agonist (Bicycle TICA), and BT7455, an EphA2/CD137 Bicycle TICA, will be presented in five poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th An |
Bicycle Therapeutics (BCYC) Gets a Buy from NeedhamNeedham analyst Ami Fadia maintained a Buy rating on Bicycle Therapeutics (BCYC - Research Report) yesterday and set a price target of $72.00. The company's shares closed yesterday at $24.68.Fadia covers the Healthcare sector, focusing on stocks such as Biogen, Avadel Pharmaceuticals, and Merus. According to TipRanks, Fadia has an average return of -0.7% and a 43.16% success rate on recommended stocks. Bicycle Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.67, which is a 109.36% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $46.00 price target. |
Bicycle Therapeutics Third Quarter 2022 Earnings: Misses ExpectationsBicycle Therapeutics ( NASDAQ:BCYC ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.04m (down 30% from... |
You Should Read This Analysis Before Investing in Bicycle Therapeutics plc (NASDAQ:BCYC)In the current trading session, Bicycle Therapeutics plc’s (BCYC) stock is trading at the price of $23.71, a gain of 1.20% over last night’s close. So, the stock is trading at a price that is -61.80% less than its 52-week high of $62.08 and 96.27% better than its 52-week low of $12.08. Based on the […] |
BCYC Price Returns
| 1-mo | 30.20% |
| 3-mo | 23.27% |
| 6-mo | 128.77% |
| 1-year | -39.80% |
| 3-year | 311.54% |
| 5-year | N/A |
| YTD | -47.87% |
| 2021 | 239.11% |
| 2020 | 90.35% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...